Edwards extends heart valve trial
This article was originally published in The Gray Sheet
Executive Summary
Firm will expand U.S. feasibility trial for its Cribier-Edwards percutaneous aortic heart valve by 35 patients before initiating a pivotal trial. Discussion with FDA about the pivotal trial design continues, but the study will not begin until all 55 patients in the current study complete six-month follow-up, according to the firm. Edwards expects a CE mark based on an ongoing European study by the end of 2007...